Advances in new targets for immunotherapy of small cell lung cancer.
Advances in new targets for immunotherapy of small cell lung cancer.
复制标题
DOI：
10.1111/1759-7714.15178
复制
发表时间：
2024-01
期刊：
影响因子：
2.9
通讯作者：
中科院分区：
文献类型：
--
作者：
小细胞肺癌(SCLC)是一种高度侵袭性的恶性肿瘤，具有生长迅速、早期转移等特点，但治疗方案有限。对于小细胞肺癌，卡铂或顺铂联合依托泊苷化疗一直被认为是唯一的治疗标准，但标准的一线治疗只会导致10个月的生存。尽管对化疗的反应相对敏感，但大多数患者在治疗后几周至几个月内复发。在过去的十年中，免疫治疗在治疗小细胞肺癌患者方面取得了重大进展。然而，目前免疫检查点抑制剂PD-1/PD-L1和CTLA-4对小细胞肺癌患者生存率的改善有限。面对小细胞肺癌复发率高、受益人群少、生存效益低的问题，探索小细胞肺癌关键分子和信号的新靶点，开发具有新机制的药物，可能为小细胞肺癌的免疫治疗带来新的希望。因此，本综述的目的是探索DLL3、TIGIT、LAG-3和GD2四个新的靶点，以期在小细胞肺癌的免疫治疗中发挥作用，寻找有用的线索和策略来改善小细胞肺癌患者的预后。免疫检查点抑制剂改变了小细胞肺癌(SCLC)的治疗模式。然而，目前的免疫疗法，如程序性细胞死亡-1(PD-1)/程序性死亡配体1(PD-L1)和细胞毒性T淋巴细胞相关抗原-4(CTLA-4)，对生存的益处有限。迫切需要开发新的靶点或免疫治疗药物。本文综述了小细胞肺癌免疫治疗的多个新靶点，包括增量样配体3(DLL3)、T细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域(TIGIT)、淋巴细胞激活基因-3(LAG-3)和二唾液酸神经节苷脂(GD2)等。
Small cell lung cancer (SCLC) is one of the highly aggressive malignancies characterized by rapid growth and early metastasis, but treatment options are limited. For SCLC, carboplatin or cisplatin in combination with etoposide chemotherapy has been considered the only standard of care, but the standard first‐line treatment only results in 10‐month survival. The majority of patients relapse within a few weeks to months after treatment, despite the relatively sensitive response to chemotherapy. Over the past decade, immunotherapy has made significant progress in the treatment of SCLC patients. However, there have been limited improvements in survival rates for SCLC patients with the current immune checkpoint inhibitors PD‐1/PD‐L1 and CTLA‐4. In the face of high recurrence rates, small beneficiary populations, and low survival benefits, the exploration of new targets for key molecules and signals in SCLC and the development of drugs with novel mechanisms may provide fresh hope for immunotherapy in SCLC. Therefore, the aim of this review was to explore four new targets, DLL3, TIGIT, LAG‐3, and GD2, which may play a role in the immunotherapy of SCLC to find useful clues and strategies to improve the outcome for SCLC patients. Immune checkpoint inhibitors have altered the treatment paradigm of small cell lung cancer (SCLC). However, the current immunotherapies, such as programmed cell death‐1 (PD‐1)/programmed death ligand 1 (PD‐L1) and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4), brought limited benefits to survival. It is urgent to develop new targets or immunotherapy drugs. This review focuses on multiple new targets of immunotherapy investigated in the field of SCLC, including delta‐like ligand 3 (DLL3), T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif structural domains (TIGIT), lymphocyte activation gene‐3 (LAG‐3), and disialoganglioside (GD2), and others.
登录
查看更多内容
影响因子：
8.8
作者：
Borromeo MD;Savage TK;Kollipara RK;He M;Augustyn A;Osborne JK;Girard L;Minna JD;Gazdar AF;Cobb MH;Johnson JE
通讯作者：
Johnson JE
影响因子：
30.5
作者：
Blackburn, Shawn D.;Shin, Haina;Haining, W. Nicholas;Zou, Tao;Workman, Creg J.;Polley, Antonio;Betts, Michael R.;Freeman, Gordon J.;Vignali, Dario A. A.;Wherry, E. John
通讯作者：
Wherry, E. John
影响因子：
3.2
作者：
通讯作者：
--
影响因子：
50.3
作者：
Gay CM;Stewart CA;Park EM;Diao L;Groves SM;Heeke S;Nabet BY;Fujimoto J;Solis LM;Lu W;Xi Y;Cardnell RJ;Wang Q;Fabbri G;Cargill KR;Vokes NI;Ramkumar K;Zhang B;Della Corte CM;Robson P;Swisher SG;Roth JA;Glisson BS;Shames DS;Wistuba II;Wang J;Quaranta V;Minna J;Heymach JV;Byers LA
通讯作者：
Byers LA
影响因子：
6.6
作者：
Dora, David;Rivard, Christopher;Lohinai, Zoltan
通讯作者：
Lohinai, Zoltan